Deciphera Pharmaceuticals (DCPH) Competitors

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.

Which has more risk and volatility, DCPH or VERV?

Deciphera Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Is DCPH or VERV more profitable?

Verve Therapeutics has a net margin of 0.00% compared to Deciphera Pharmaceuticals' net margin of -131.38%. Verve Therapeutics' return on equity of -37.63% beat Deciphera Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Deciphera Pharmaceuticals	-131.38%	-46.56%	-36.58%
Verve Therapeutics	N/A	-37.63%	-31.01%

Does the media refer more to DCPH or VERV?

In the previous week, Deciphera Pharmaceuticals and Deciphera Pharmaceuticals both had 5 articles in the media. Deciphera Pharmaceuticals' average media sentiment score of 0.72 beat Verve Therapeutics' score of 0.63 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Deciphera Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verve Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of DCPH or VERV?

72.7% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Verve Therapeutics shares are held by institutional investors. 4.4% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 21.4% of Verve Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in DCPH or VERV?

Deciphera Pharmaceuticals received 301 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 65.48% of users gave Deciphera Pharmaceuticals an outperform vote while only 41.38% of users gave Verve Therapeutics an outperform vote.

Company	Underperform	Outperform
Deciphera Pharmaceuticals	Outperform Votes 313 65.48%	Underperform Votes 165 34.52%
Verve Therapeutics	Outperform Votes 12 41.38%	Underperform Votes 17 58.62%

Which has higher valuation & earnings, DCPH or VERV?

Verve Therapeutics has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Deciphera Pharmaceuticals	$134.04 million	8.21	-$178.93 million	-$2.35	-5.97
Verve Therapeutics	$1.94 million	548.66	-$157.39 million	-$3.14	-5.47

Do analysts rate DCPH or VERV?

Deciphera Pharmaceuticals currently has a consensus price target of $21.78, indicating a potential upside of 55.33%. Verve Therapeutics has a consensus price target of $38.63, indicating a potential upside of 124.69%. Given Verve Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Deciphera Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Deciphera Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Verve Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Verve Therapeutics beats Deciphera Pharmaceuticals on 10 of the 17 factors compared between the two stocks.